SG&A at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's SG&A?
- Corcept Therapeutics (CORT) reported SG&A of $145.36M in Q1 2026.
- How has Corcept Therapeutics's SG&A changed year-over-year?
- Corcept Therapeutics's SG&A increased by 60.3% year-over-year, from $90.66M to $145.36M.
- What is the long-term trend for Corcept Therapeutics's SG&A?
- Over 4 years (2021 to 2025), Corcept Therapeutics's SG&A has grown at a 38.4% compound annual growth rate (CAGR), from $122.36M to $448.73M.
- What does SG&A mean?
- The overhead costs of running a business, including sales, marketing, and administrative salaries.
- How do you interpret SG&A?
- An increase relative to revenue may indicate aggressive commercial expansion or inefficient corporate overhead.
- How does SG&A compare across companies?
- Varies by commercial stage; companies in the launch phase often have higher SG&A relative to revenue than established peers.